This Pill Will Change Cancer Treatment Forever

Key Points:

• Revolution Medicines won the 2026 Gizmodo Science Fair for developing Rasonque (daraxonrasib), the first approved RAS(ON) inhibitor cancer drug targeting pancreatic ductal adenocarcinoma, significantly improving survival rates.
• In a clinical trial of 500 patients with metastatic pancreatic cancer, daraxonrasib doubled median survival to 13.2 months compared to 6.7 months with standard chemotherapy, with minimal discontinuation due to side effects.
• Daraxonrasib works by directly inhibiting mutant RAS proteins stuck in an active state, a breakthrough in targeting a protein long considered "undruggable" and responsible for about 90% of pancreatic cancers.
• While not a cure, daraxonrasib offers the first effective targeted treatment option for pancreatic cancer patients who have exhausted other therapies, and Revolution Medicines is conducting further trials to expand its use and develop additional RAS-focused drugs.
• The company’s success stems from multidisciplinary collaboration and strategic acquisitions, with ongoing trials exploring RAS-targeted treatments for other cancers such as colorectal and lung adenocarcinomas, offering hope to thousands of patients annually.